

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING D.	ATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/926,385	10/24/2001		Takashi Tojo	215095US0PCT	1263
22850	7590 03/05/2004			EXAMINER	
OBLON, S 1940 DUKE	PIVAK, MCCI STREET	LUKTON, DAVID			
ALEXANDRIA, VA 22314				ART UNIT	PAPER NUMBER
				1653	

DATE MAILED: 03/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
•	09/926,385	TOJO ET AL.
Office Action Summary	Examiner	Art Unit
•	David Lukton	1653
The MAILING DATE of this communication		1 I
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR RE THE MAILING DATE OF THIS COMMUNICATIO - Extensions of time may be available under the provisions of 37 CFF after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a reply within the statutory minimum of thir irod will apply and will expire SIX (6) MON atute. cause the application to become A	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. & 133)
Status		
1) Responsive to communication(s) filed on 14	4 November 2003.	
	his action is non-final.	
3) Since this application is in condition for allow	wance except for formal mat	ters, prosecution as to the merits is
closed in accordance with the practice unde	er <i>Ex parte Quayl</i> e, 1935 C.D). 11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) <u>1-12</u> is/are pending in the applicati	ion.	
4a) Of the above claim(s) is/are without		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-12</u> are subject to restriction and/	or election requirement.	
Application Papers		
9) The specification is objected to by the Exam	iner.	
10) ☐ The drawing(s) filed on is/are: a) ☐ a		by the Examiner
Applicant may not request that any objection to t		
Replacement drawing sheet(s) including the corr		
11) The oath or declaration is objected to by the		
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for forei	ian priority under 35 U.S.C. &	(110(a) (d) or (f)
a) ☐ All b) ☐ Some * c) ☐ None of:	gri priority under 35 0.5.C. §	; 119(a)-(u) or (i).
1. Certified copies of the priority docume	ante have been received	
2. Certified copies of the priority docume		nnlication No
3. Copies of the certified copies of the pi		
application from the International Bure		received in this National Stage
* See the attached detailed Office action for a li		received
and and an animod dollars of the animod doll	or and definied dopies flot	TOOMYSU.
Attachment(s) 1) Notice of References Cited (PTO-892)	 □	(DTO 440)
2) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)		Summary (PTO-413) s)/Mail Date
B) 🔲 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0	08) 5) Notice of In	nformal Patent Application (PTO-152)
Paper No(s)/Mail Date	6)	 '

Restriction to one of the following inventions is required under 35 U.S.C. §121:

- I. Claims 1-7, 9 and 11, drawn to compounds.
- II. Claim 8, drawn to a method of making compounds.
- III. Claim 12, drawn to a method of using compounds.

Claim 10 is not grouped. In the event that this claim is revised so that the subject matter falls within a proper statutory class of invention, this claim will be grouped accordingly.

The claimed inventions are distinct.

Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP 806.05(f)). However, in the event that Group I is elected, and claims therein found allowable, the corresponding method-of-making claims will be rejoined therewith.

Inventions I and III are related as product and process of use. However, in the event that Group I is elected, and claims therein found allowable, the corresponding method-of-use claims will be rejoined therewith.

Serial No. 09/926,385 Art Unit 1653

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

In addition to the foregoing, applicant is required under 35 U.S.C. §121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Regardless of which Group is chosen for initial examination, election of a specific compound is required. The compounds should be fully defined so that all of the atoms in the molecule are accounted for. A statement that, for example, R¹ is "acyl" would be considered non-responsive, since "acyl" is a generic term.

In the event that Group II is chosen for initial examination, two elections are required: (a) election of a compound that is the "target" of the synthesis, and (b) a process used to synthesize the target, i.e., the process identified as i, ii, iii, iv, v, vi or vii in claim 8.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the

Serial No. 09/926, 385 Art Unit 1653

limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 0.6. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached at 571-272-0951. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

PATENT EXAMPLES
GROUP INC